Dr. Falk Pharma GMBH v. Generico, LLC, No. 17-2312 (Fed. Cir. 2019)
Annotate this CaseThe Katten law firm signed an engagement letter with Bausch & Lomb, a corporate affiliate of Valeant, that broadly defined Katten’s client as any Valeant entity. Attorneys Mukerjee and Soderstrom represented Mylan during various stages of proceedings in which Valeant was adverse, first, as Alston & Bird attorneys, but later, as Katten attorneys. Valeant and others moved to disqualify Katten as counsel for Mylan in three pending appeals concerning patents and trademarks. The Federal Circuit granted those motions. Katten has an ongoing attorney-client relationship with Valeant and its subsidiaries, so Katten’s representation of Mylan in these appeals presents concurrent conflicts of interest in violation of Rule 1.7(a) of the Model Rules of Professional Conduct.
The court issued a subsequent related opinion or order on June 12, 2019.
The court issued a subsequent related opinion or order on July 11, 2019.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.